SII CEO Adar Poonawalla to get ‘Y’ category security
By Mansoor| Published: 28th April 2021 8:10 pm IST Serum Institute of India s CEO Adar Poonawalla
New Delhi: Serum Institute of India’s CEO Adar Poonawalla will get ‘Y’ category security across India by the CRPF, the Union government officials said on Wednesday.
The Union government’s decision came after Director, Government and Regulatory Affairs at Pune-based Serum Institute of India (SII), Prakash Kumar Singh had written to Union Home Minister Amit Shah on April 16 requesting security for Poonawalla.
Covishield, one of the two COVID-19 vaccines used in India’s COVID-19 vaccination programme, is being manufactured by SII.
Serum CEO Adar Poonawalla to get Y category security cover: MHA business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
NEW DELHI: World s largest vaccine manufacturer by volume, Serum Institute of India, has sought Union home minister Amit Shah s intervention in bringing changes in the Air Operations Routine (AOR) issuance policy at the Pune airport for smooth operation of non-scheduled aircraft.
In a recent letter to Shah, the Pune-based firm suggested amendments in the AOR policy stating, it is needed for foreigners to commute smoothly at the airport and encourage ease of doing business in India .
The Pune airport is a defence airfield that operates under the Indian Air Force (IAF). Because of this, AOR is required for the foreign passengers, pilots and crew members coming to Pune by non-scheduled flights, said Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), in the letter.
Government places second purchase order with SII for one crore doses of Covishield
The HLL Lifecare Limited, a public sector undertaking, on behalf of the Union health ministry issued the supply order in the name of Prakash Kumar Singh.
Share Via Email
| A+A A-
A health worker shows the Covishield vaccine, after arrival of the first batch from the Serum Institute of India at the Ahmedabad Civil Hospital. (Photo | EPS) By PTI
NEW DELHI: The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine Covishield , each costing Rs 210, including GST, sources said.
NEW DELHI: The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca Covid-19 vaccine ‘Covishield , each costing Rs 210, including GST, sources said.
The HLL Lifecare Limited, a public sector undertaking, on behalf of the Union health ministry issued the supply order in the name of Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), Pune.
The government had on January 11 placed an order for 1.1 crore doses of Covishield at a cost of Rs 231 crore, which has now risen to Rs 441 crore with the second order placed on Wednesday, a source said.